Migraine

Nontraditional risk factors such as migraine, valvular heart disease and thrombophilia may be linked to increased risk for stroke among younger adults, researchers reported.

Migraine plus persistent vasomotor symptoms is associated with greater CVD risk and stroke for women, according to a secondary data analysis published in Menopause.

A new direct-to-consumer health care program launched by Eli Lilly has the potential to improve access to diabetes, obesity and migraine medications in the United States.

Patients who are hospitalized with stroke-like symptoms, but do not experience a stroke, may yet develop PTSD at a higher rate than patients who actually had a stroke, a speaker reported.

Older adults recently diagnosed with migraine were more than three times likely to be involved in a motor vehicle crash within a year compared with those who never had a migraine diagnosis, according to researchers.

Treatment with 100 mg of ubrogepant in the prodromal phase prevented development of headaches as soon as 24 hours post-dose compared with placebo, according to study co-author Peter J. Goadsby, MD, PhD, FRS.

Healio Neurology looks back at the most-viewed stories throughout the year. Highlights include the FDA’s approval of Leqembi to treat Alzheimer’s disease and the regulatory body’s clearing of a blood test for concussions.

Developments in spectacle lenses over the past year have revealed their efficacy beyond vision correction.

Among seven classes and 25 individual medications, triptans, ergots and anti-emetics were the most effective acute treatments for individuals with migraine, according to research published in Neurology.

Treatment with 100 mg ubrogepant was effective at curbing migraine attacks when administered during the prodromal phase compared with placebo, according to research from The Lancet.